We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
-$396M
Cap. Flow %
-22.17%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 10.45%
2 Energy 0.15%
3 Communication Services 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
201
PUT
EyePoint Inc
EYPT
$1B
$262K 0.01%
+64
New +$2.82K
AMPE
202
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$260K 0.01%
137
+61
+80% +$144K
OMER icon
203
Omeros
OMER
$816M
$241K 0.01%
+20,000
New +$246K
ALKS icon
204
Alkermes
ALKS
$8.47B
$226K 0.01%
+5,126
New +$244K
SLXP
205
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$225K 0.01%
+2,170
New +$222K
MNTA
206
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$213K 0.01%
+18,274
New +$309K
ATHX
207
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
$191K 0.01%
24
+10
+71% +$924
ADXSW
208
DELISTED
Advaxis Inc Warrants
ADXSW
$181K 0.01%
144,935
-17,440
-11% -$32.9K
CORT icon
209
CALL
Corcept Therapeutics
CORT
$10.1B
$174K 0.01%
+400
New +$1.4K
ACGN
210
CALL
DELISTED
Aceragen Inc
ACGN
$162K 0.01%
+3
New +$2.05K
NBIX icon
211
PUT
Neurocrine Biosciences
NBIX
$18.4B
$161K 0.01%
+100
New +$1.71K
TENX icon
212
CALL
Tenax Therapeutics
TENX
$419M
– –
0
– –
CASC
213
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
$152K 0.01%
85
-28
-25% -$460
DYAX
214
CALL
DELISTED
DYAX CORPORATION
DYAX
$146K 0.01%
163
-75
-32% -$682
FOCL
215
CALL
EDAP TMS S.A.
FOCL
$227M
$143K 0.01%
+500
New +$1.59K
CEMP
216
CALL
DELISTED
Cempra, Inc.
CEMP
$140K 0.01%
+121
New +$1.5K
VVUS
217
DELISTED
Vivus Inc
VVUS
$131K 0.01%
+2,203
New +$157K
PGNX
218
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$122K 0.01%
298
– –
CRDF icon
219
Cardiff Oncology
CRDF
$63.6M
$115K 0.01%
278
– –
VVUS
220
PUT
DELISTED
Vivus Inc
VVUS
$112K 0.01%
19
-141
-88% -$10K
ANTH
221
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$108K 0.01%
40
+2
+5% +$51
ASRT
222
CALL
DELISTED
Assertio
ASRT
$103K 0.01%
+9
New +$6.86K
AGEN
223
PUT
Agenus
AGEN
$275M
$78K ﹤0.01%
+12
New +$834
FOCL
224
EDAP TMS S.A.
FOCL
$227M
$66K ﹤0.01%
23,200
-747,418
-97% -$2.37M
ATHE
225
PUT
Alterity Therapeutics
ATHE
$82.7M
$62K ﹤0.01%
+4
New +$2.21K
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.

Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.